These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 11464832)

  • 1. Hepatitis B, lamivudine, and HIV.
    Kuchimanchi U; Rooney G
    BMJ; 2001 Jul; 323(7303):51. PubMed ID: 11464832
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.
    Matthews GV; Dore GJ
    AIDS; 2007 Mar; 21(6):777-8. PubMed ID: 17413705
    [No Abstract]   [Full Text] [Related]  

  • 3. The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?
    Puoti M; Cozzi-Lepri A; Ancarani F; Bruno R; Ambu S; Ferraro T; Tundo P; Santantonio T; Toti M; Bonasso M; d'Arminio Monforte A; ;
    Antivir Ther; 2004 Oct; 9(5):811-7. PubMed ID: 15535419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lamivudine resistance impedes hepatitis B therapy].
    Eggers HJ
    Fortschr Med; 1997 Apr; 115(12):5. PubMed ID: 9235306
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment: a tale of two viruses.
    Dieterich DT
    AIDS Read; 2002 Oct; 12(10):448-9. PubMed ID: 12408102
    [No Abstract]   [Full Text] [Related]  

  • 7. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
    Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
    AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of long-term lamivudine treated chronic HBV infected and HIV/HBV coinfected patients.
    Elefsiniotis IS; Paparizos V; Dourakis SP; Mpotsi C; Pantazis KD; Katsambas N
    J Clin Virol; 2005 May; 33(1):80-2. PubMed ID: 15797371
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
    Schmutz G; Nelson M; Lutz T; Sheldon J; Bruno R; von Boemmel F; Hoffmann C; Rockstroh J; Stoehr A; Wolf E; Soriano V; Berger F; Berg T; Carlebach A; Schwarze-Zander C; Schürmann D; Jaeger H; Mauss S
    AIDS; 2006 Oct; 20(15):1951-4. PubMed ID: 16988516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamivudine-resistant hepatitis B detected in HIV-infected patients.
    Newsline People AIDS Coalit N Y; 1999 Jan; ():36. PubMed ID: 11367194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
    Bani-Sadr F; Palmer P; Scieux C; Molina JM
    Clin Infect Dis; 2004 Oct; 39(7):1062-4. PubMed ID: 15472862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
    Van Bömmel F; Schernick A; Hopf U; Berg T
    Gastroenterology; 2003 Feb; 124(2):586-7. PubMed ID: 12557178
    [No Abstract]   [Full Text] [Related]  

  • 13. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART.
    Drake A; Mijch A; Sasadeusz J
    Clin Infect Dis; 2004 Jul; 39(1):129-32. PubMed ID: 15206064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation.
    Seehofer D; Rayes N; Steinmüller T; Müller AR; Settmacher U; Neuhaus R; Radke C; Berg T; Hopf U; Neuhaus P
    Liver Transpl; 2001 Nov; 7(11):976-82. PubMed ID: 11699034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic hepatitis B in HIV co-infected patients.
    Guan R
    Med J Malaysia; 2005 Jul; 60 Suppl B():52-6. PubMed ID: 16108174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.
    Tamalet C; Tomei C; Henry M; Solas C; Villacian J; Colson P
    AIDS; 2007 Nov; 21(18):2551-2. PubMed ID: 18025898
    [No Abstract]   [Full Text] [Related]  

  • 17. Food and Drug Administration approves lamivudine for hepatitis B.
    Front Med Biol Eng; 1999; 9(1):95. PubMed ID: 10354913
    [No Abstract]   [Full Text] [Related]  

  • 18. 3TC recommended for hepatitis B.
    Body Posit; 1999 Apr; 12(4):39. PubMed ID: 11366278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus and hepatitis B virus co-infection in two siblings: viral loads markedly reduced by triple-therapy including lamivudine.
    Horneff G; Niehues T; Adams O; Braunstein S; Wahn V
    Eur J Pediatr; 1999 Aug; 158(8):687-8. PubMed ID: 10445356
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.